Tissue Modeling & Drug Development Shared Resources Core

摘要-组织建模和药物开发核心（共享资源） 佛罗里达-加利福尼亚癌症研究，教育和参与（CaRE 2）健康公平中心的目标 组织建模和药物开发核心（TMDDC）是提供一个不断增长的档案固定和活组织 这将支持CARE 2中心的使命。在第一个融资周期（周期1），我们非常成功 FAMU和CaRE 2研究人员获得了来自黑人/非裔美国人（B/AA）的注释组织 西班牙裔/拉丁裔（H/L）总的来说，TMDDC现在可以在整个合作伙伴关系中获得符合监管要求的访问权限， 癌症病例包括胰腺癌组织块（295 B/AA，306 H/L）、胰腺癌血浆/血清（136 B/AA，53 H/L）、前列腺癌组织块（548 B/AA，195 H/L）和前列腺血浆/血清（595 B/AA，92 H/L）。 此外，TMDDC促进了4种新的来自B/AA的患者源性异种移植物（PDX）的产生或鉴定 FAMU和USC的胰腺癌患者的研究。TMDDC将继续开发一个强大的， 来自种族和民族多样性佛罗里达的固定和活组织样本的注释良好的生物储存库， 加州患者人群，并将其提供给CaRE 2研究者。TMDDC将包括 现有的机构，国家共享和未来意识的生物资源。短期目标是 TMDDC将为本申请中包含的三个项目提供必要的组织样本， 为现有和即将到来的CARE 2中心项目的未来需求做准备。TMC将解决 在医学研究中招募B/AA和H/L个人的挑战以及质量有限的供应 生物标本和基因组数据。我们的具体目标是：目标1。推进现有的 虚拟和物理存储库将越来越多地提供来自不同肿瘤存储库的生物标本 通过由CARE 2中心提供的单一接入点。许多癌症类型和许多组织模型是 与差异研究的结果相关。研究这些复杂的组织和数据所需的广泛类型 这些问题使得获得一个完全令人满意的存储处超出了任何单一机构的能力范围。因此，我们认为， 我们将通过我们的研究，发展收集或获得新颖多样和注释良好的标本的能力。 机构资源和其他资源。目标2.获取活体肿瘤组织用于药物开发。个pdx 已经证明比历史上使用的细胞系衍生的研究更好地预测人类药物反应。发展 这些PDX具有促进快速药物开发的潜力，包括测试响应作为以下功能的函数： 种族/血统。TMDDC将推进FAMU现有的第1周期开发组织库。TMDDC 将在FAMU现有的活组织储存库上取得进展。为达致这些目标，我们会： 癌症差异组织建模研究;（2）为CaRE 2研究人员扩展癌症差异资源， 以及（3）确保持续关注专有技术、技术的转让以及与FAMU的合作。 评估将基于项目所需标本/资源的充分提供，以及 向FAMU转让药物开发技术和专有技术。

ABSTRACT – TISSUE MODELING & DRUG DEVELOPMENT CORE (SHARED RESOURCE) The goal of the Florida-California Cancer Research, Education, & Engagement (CaRE2) Health Equity Center’s Tissue Modeling and Drug Development Core (TMDDC) is to provide a growing archive of fixed and living tissues that will support the mission of the CaRE2 Center. In the first funding period (Cycle 1), we were highly successful in gaining access for FAMU and CaRE2 researchers to annotated tissues from Black/African American (B/AA) and Hispanic/Latinx (H/L). In total, the TMDDC now has regulatory compliant access across the partnership to cancer cases including pancreatic cancer blocks (295 B/AA, 306 H/L), pancreatic cancer plasma/serum (136 B/AA, 53 H/L), prostate cancer blocks (548 B/AA, 195 H/L), and prostate plasma/serum (595 B/AA, 92 H/L). Also, the TMDDC facilitated creation or identification of 4 new patient-derived xenografts (PDX) from B/AA patients with pancreatic cancer for studies at FAMU and USC. The TMDDC will continue to develop a robust, well-annotated biorepository of fixed and living tissue samples from a racially and ethnically diverse Florida and California patient population and make them available to the CaRE2 investigators. The TMDDC will consist of existing institutional, nationally shared, and future-conscious biorepository resources. The short-term goals of the TMDDC are to provide the necessary tissue samples for the three projects included in this application, while preparing for the future needs of the existing and upcoming CaRE2 Center projects. The TMC will address the challenge of recruiting B/AA and H/L individuals in medical research and the limited supply of quality biospecimens and genomic data for these populations. Our specific aims are to: Aim 1. Advance our existing virtual and physical repositories that will increasingly provide biospecimens from diverse tumor repositories through a single access point provided by the CaRE2 Center. Many cancer types and many tissue models are relevant to outcomes in disparities research. The broad types of tissues and data required to study these complex issues make acquisition of a fully satisfactory repository beyond the scope of any single institution. Therefore, we will develop capabilities to collect or acquire novel diverse and well annotated specimens through our institutional resources and other resources. Aim 2. Acquire living tumor tissue for drug development. PDXs have proven to better predict human drug responses than historically used cell-line derived studies. Development of these PDXs has the potential to facilitate rapid drug development, including testing response as a function of race/ancestry. The TMDDC will advance the existing Cycle 1 developed tissue repository at FAMU. The TMDDC will advance on the existing living tissue repository at FAMU. By achieving these aims, we will: (1) enhance cancer disparities tissue-modeling research; (2) expand cancer disparities resources for CaRE2 researchers, and (3) ensure a sustained focus on transferring know-how, technology, and collaborations with FAMU. Evaluation will be based on adequate provision of project-required specimens/resources and by success in transferring drug development technology and knowhow to FAMU.